

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Cunningham 1



Section 1. Identifying Inform	nation		
Given Name (First Name) Trevor	2. Surname (Last Name) Cunningham	an a silat a li silaterico	3. Date 29-August-2016
4. Are you the corresponding author?	Yes No	Corresponding Author's Na Shadmehr Demehri	me de la la composite de la co
5. Manuscript Title Calcipotriol and 5-Fluorouracil Combina	ation for Actinic Keratosis I	mmunotherapy: Double-B	lind, Randomized Clinical Trial
6. Manuscript Identifying Number (if you kr 89820-JCI-CMED	now it)		
Section 2. The Work Under Co	onsideration for Public	ation	
Did you or your institution at any time receiving aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of interest.	but not limited to grants, dat		
Section 3. Relevant financial	activities outside the s	ubmitted work.	
Place a check in the appropriate boxes i of compensation) with entities as descri clicking the "Add +" box. You should rep Are there any relevant conflicts of interes	bed in the instructions. Use port relationships that were	e one line for each entity; a	add as many lines as you need by
Section 4. Intellectual Proper	ty Patents & Copyrig	hts	
Do you have any patents, whether plant	ned, pending or issued, bro	oadly relevant to the work?	? Yes 🗸 No



Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
	wing relationships/conditions/circumstances are present (explain below): tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
below.	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Dr. Cunningham	has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Cunningham



Section 1. Identifying Inform	nation		
1. Given Name (First Name) Mary	2. Surname (Last Name) Tabacchi		3. Date 29-August-2016
4. Are you the corresponding author?	Yes No	Corresponding Author's Na Shadmehr Demehri	ime
5. Manuscript Title Calcipotriol and 5-Fluorouracil Combin	nation for Actinic Keratosis	Immunotherapy: Double-B	lind, Randomized Clinical Trial
6. Manuscript Identifying Number (if you k 89820-JCI-CMED	now it)	and the second of the second o	
FASTER WELL VIOLEN			
Section 2. The Work Under C	onsideration for Public	cation	
Did you or your institution at any time rece any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of inter	g but not limited to grants, da		
Section 3. Relevant financial	activities outside the s	submitted work.	
Place a check in the appropriate boxes of compensation) with entities as describing the "Add +" box. You should re Are there any relevant conflicts of inter	ribed in the instructions. Us port relationships that wer	se one line for each entity;	add as many lines as you need by
		THE CASE OF THE PARTY OF	
Section 4. Intellectual Prope	rty Patents & Copyric	ghts	经 国建筑设施的
Do you have any patents, whether plan	nned, pending or issued, br	oadly relevant to the work	? Yes V No

Tabacchi 2



Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below): No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure stateme On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Tabacchi has nothing to disclose.

Evaluation and Feedback



Section 1. Identifying Infor	mation	
Given Name (First Name) Jean-Pierre	2. Surname (Last Name) Eliane	3. Date 29-August-2016
4. Are you the corresponding author?	Yes No Corresponding Author's Shadmehr Demehri	Name
5. Manuscript Title Calcipotriol and 5-Fluorouracil Combi	nation for Actinic Keratosis Immunotherapy: Double	e-Blind, Randomized Clinical Trial
6. Manuscript Identifying Number (if you l 89820-JCI-CMED	know it)	
Section 2. The Work Under 0	Consideration for Publication	
	eive payment or services from a third party (government, ng but not limited to grants, data monitoring board, study rest? Yes V No	
Section 3. Relevant financia	l activities outside the submitted work.	
of compensation) with entities as desc	in the table to indicate whether you have financial ribed in the instructions. Use one line for each entity eport relationships that were present during the 3 0 rest?	y; add as many lines as you need by
Section 4. Intellectual Prope	erty Patents & Copyrights	
Do you have any patents, whether plan	nned, pending or issued, broadly relevant to the wo	ork? Yes V No



Section 5.		
	Relationships not covered above	
	relationships or activities that readers could perceive uencing, what you wrote in the submitted work?	to have influenced, or that give the appearance of
	owing relationships/conditions/circumstances are pre	Contraction (Contraction € at the Contract (Contraction Contraction Contracti
✓ No other rel	lationships/conditions/circumstances that present a p	potential conflict of interest
	nanuscript acceptance, journals will ask authors to cor urnals may ask authors to disclose further information	nfirm and, if necessary, update their disclosure statements. n about reported relationships.
Section 6.	Disclosure Statement	
	oove disclosures, this form will automatically generate	a a disclosure statement, which will appear in the how
below.		
The section		
5 PS no 71 no 5 Sudi		
1 25 to 5 to 6	Constraints at the state of the	

Evaluation and Feedback



Section 1. Identifying Inform	mation		
1. Given Name (First Name) Sara	2. Surname (Last Name) Moradi Tuchayi		3. Date 29-August-2016
4. Are you the corresponding author?	Yes No	Corresponding Author's Na Shadmehr Demehri	ame and approximate the second
5. Manuscript Title Calcipotriol and 5-Fluorouracil Combin	nation for Actinic Keratosis	Immunotherapy: Double-B	Blind, Randomized Clinical Trial
6. Manuscript Identifying Number (if you k 89820-JCI-CMED	know it)		
Section 2. The Work Under (Consideration for Publi	cation	
Did you or your institution at any time recany aspect of the submitted work (includin statistical analysis, etc.)? Are there any relevant conflicts of inte	ng but not limited to grants, da		
Section 3. Relevant financia	l activities outside the s	submitted work.	
Place a check in the appropriate boxes of compensation) with entities as descricking the "Add +" box. You should re Are there any relevant conflicts of interesting the second conflicts of the second	ribed in the instructions. Use port relationships that we	se one line for each entity;	add as many lines as you need by
Section 4. Intellectual Prope	erty Patents & Copyri	ghts	
Do you have any patents, whether plan	nned, pending or issued, br	oadly relevant to the work	? Yes 🗸 No

Moradi Tuchayi

2



		1		
Section 5.	Relationships not covered above			建工机构的基本
	elationships or activities that readers cou encing, what you wrote in the submitted		have influenced, or tha	it give the appearance of
	wing relationships/conditions/circumstartionships/conditions/circumstances that			ndrode ye n Payan
V 1.0 other read	tionships, conditions, circumstances that	present a pot	ential conflict of interes	. 21
At the time of ma On occasion, jou	anuscript acceptance, journals will ask au rnals may ask authors to disclose further	thors to confir	rm and, if necessary, up bout reported relations	date their disclosure statements. hips.
Section 6.				Variable of the second second second
Section 6.	Disclosure Statement			
	ve disclosures, this form will automatical	ly generate a	disclosure statement, w	hich will appear in the box
below.				
eg esque	to an a sol = remarks in the			and the proof of the following
Dr. Moradi Tucha	ayi has nothing to disclose.	11.		Line of the second of the second
				:
	A STATE OF THE STA	L LEKE		

Evaluation and Feedback



Section 1. Identifying I	nformation		
Given Name (First Name) Sindhu	2. Surname (Last Name) Manivasagam		3. Date 29-August-2016
4. Are you the corresponding author	? Yes No	Corresponding Author's Na Shadmehr Demehri	ame
5. Manuscript Title Calcipotriol and 5-Fluorouracil Co	mbination for Actinic Keratosis	Immunotherapy: Double-B	Blind, Randomized Clinical Trial
6. Manuscript Identifying Number (if 89820-JCI-CMED	you know it)		ப சத்த ¹ - ம ஆ் _க = − மலக்க
to butto the same			
Section 2. The Work Und	der Consideration for Publi	cation	
Did you or your institution at any time any aspect of the submitted work (inconstatistical analysis, etc.)? Are there any relevant conflicts of	cluding but not limited to grants, d		ommercial, private foundation, etc.) for esign, manuscript preparation,
Section 3. Relevant fina	ncial activities outside the	submitted work.	
Place a check in the appropriate k of compensation) with entities as clicking the "Add +" box. You sho Are there any relevant conflicts of	described in the instructions. U uld report relationships that we	se one line for each entity;	
		white it.	
Section 4. Intellectual P	roperty Patents & Copyri	ghts	
Do you have any patents, whethe	r planned, pending or issued, b	roadly relevant to the work	? Yes V No



Section 5.	Relationships not covered above	
	relationships or activities that readers could perceive to have inflencing, what you wrote in the submitted work?	uenced, or that give the appearance of
) <u> </u>	owing relationships/conditions/circumstances are present (explain ationships/conditions/circumstances that present a potential cor	
	nanuscript acceptance, journals will ask authors to confirm and, if urnals may ask authors to disclose further information about repo	
Section 6.	Disclosure Statement	
below.	ove disclosures, this form will automatically generate a disclosure	
Dr. Manivasaga	m has nothing to disclose.	v

Evaluation and Feedback



Section 1. Identifying Infor	mation		
Given Name (First Name) Hengameh	2. Surname (Last Na Mirzaalian		e gust-2016
4. Are you the corresponding author?	Yes No	Corresponding Author's Name Shadmehr Demehri	ar , ye diperi
5. Manuscript Title Calcipotriol and 5-Fluorouracil Combi	nation for Actinic Kera	atosis Immunotherapy: Double-Blind, Ra	ndomized Clinical Trial
6. Manuscript Identifying Number (if you 89820-JCI-CMED	know it)		
Section 2. The Work Under	Consideration for I	Publication	
Did you or your institution at any time recany aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of interesting the state of the state	ng but not limited to gra	es from a third party (government, commerciants, data monitoring board, study design, ma	al, private foundation, etc.) for anuscript preparation,
Section 3. Relevant financia	l activities outside	the submitted work.	
of compensation) with entities as desc	cribed in the instruction eport relationships the	ate whether you have financial relationshons. Use one line for each entity; add as roat were present during the 36 months No	nany lines as you need by
PART AND LOCATION TO A			
Section 4. Intellectual Prop	erty Patents & Co	opyrights	
Do you have any patents, whether pla	nned, pending or issu	ued, broadly relevant to the work?	es 🔽 No



Section 5.	Relationships not covered above	
	relationships or activities that readers could perceive to have influenced, or that give the appea encing, what you wrote in the submitted work?	rance of
	owing relationships/conditions/circumstances are present (explain below): ationships/conditions/circumstances that present a potential conflict of interest	
At the time of ma On occasion, jou	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosurnals may ask authors to disclose further information about reported relationships.	sure statements.
Section 6.	Disclosure Statement	
Based on the abo below.	ove disclosures, this form will automatically generate a disclosure statement, which will appear	in the box
Dr. Mirzaalian ha	as nothing to disclose.	

Evaluation and Feedback



Section 1. Identifying Info	rmation		
1. Given Name (First Name) Ahu	2. Surname (Last Name) Turkoz	3. Date 29-August-2016	
4. Are you the corresponding author?	Yes V No	Corresponding Author's Name Shadmehr Demehri	
5. Manuscript Title Calcipotriol and 5-Fluorouracil Comb	ination for Actinic Keratosis	Immunotherapy: Double-Blind, Randomized Clinica	al Trial
6. Manuscript Identifying Number (if you 89820-JCI-CMED	know it)		
Links and the s	(A) (1) (1) (1)		
Section 2. The Work Under	Consideration for Publi	cation	
	ing but not limited to grants, do	a third party (government, commercial, private foundati ata monitoring board, study design, manuscript preparati	
Section 3. Relevant financia	al activities outside the	submitted work.	
of compensation) with entities as des	cribed in the instructions. Ureport relationships that we	ether you have financial relationships (regardless o se one line for each entity; add as many lines as you re present during the 36 months prior to publica	need by
Section 4. Intellectual Prop	erty Patents & Copyri	ghts	
Do you have any patents, whether pla	anned, pending or issued, b	roadly relevant to the work? Yes V No	

Turkoz

2



Section 5.	Relationships not covered abov	e		
	relationships or activities that readers co encing, what you wrote in the submitte	and the state of t	ave influenced, or that gi	ve the appearance of
	wing relationships/conditions/circumstationships/conditions/circumstances the		20	
	anuscript acceptance, journals will ask a Irnals may ask authors to disclose furthe			
Section 6.	Disclosure Statement			
Based on the abo	ove disclosures, this form will automatio		sclosure statement, whic	
16211	in Brownia (* 5 januari * mardinga	e " e e e e e	rail yr nglygyğr y rarn	el alte, in para a septem-
Dr. Turkoz has n	othing to disclose.			* - Albert on SM to 4 g

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Turkoz 3



Section 1.	Identifying Inform	mation		
1. Given Name (F Raphael	irst Name)	2. Surname (Last Name) Kopan		3. Date 29-August-2016
4. Are you the co	rresponding author?	Yes No	Corresponding Author's N Shadmehr Demehri	Name
5. Manuscript Titl Calcipotriol and		nation for Actinic Keratosis	Immunotherapy: Double-	Blind, Randomized Clinical Trial
6. Manuscript Ide 89820-JCI-CME	entifying Number (if you k O	now it)		
43 K 1				
Section 2.	The Work Under C	Consideration for Public	cation	
Section 3.	Relevant financia	activities outside the s	submitted work.	
of compensation clicking the "Add	n) with entities as desc	ribed in the instructions. Use port relationships that we	se one line for each entity	elationships (regardless of amount ; add as many lines as you need by months prior to publication.
19 18 1	A. P. D. W. T. C.			
Section 4.	Intellectual Prope	rty Patents & Copyri	ghts	
If yes, please fill	A SAMPLE CONTRACTOR OF THE PROPERTY OF THE PRO	and the signal and th	70	k? Ves No No ress the "ADD" button to add a row.
Pater	Pend	ing? Issued? Licensed?	Royalties Licensee?	Comments
PCT/US2015/049434				

2



Section 5.		600
Section 5.	Relationships not covered above	
	relationships or activities that readers could perceive to have influenced, or that give the appearance of sencing, what you wrote in the submitted work?	f
Yes, the follo	owing relationships/conditions/circumstances are present (explain below):	
✓ No other rela	ationships/conditions/circumstances that present a potential conflict of interest	
	nanuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure stat urnals may ask authors to disclose further information about reported relationships.	ements.
	_	
Section 6.	Disclosure Statement	
Based on the ab below.	oove disclosures, this form will automatically generate a disclosure statement, which will appear in the b	ох
e spot		
Dr. Kopan repor	rts In addition, Dr. Kopan has a patent PCT/US2015/049434 issued.	unigh
		1383 K

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Kopan



Section 1. Identifying Inform	ation		
Given Name (First Name) Andras	2. Surname (Last Name) Schaffer	п , тту — т	3. Date 29-August-2016
4. Are you the corresponding author?	Yes No	Corresponding Author Shadmehr Demehri	's Name
5. Manuscript Title Calcipotriol and 5-Fluorouracil Combina	ation for Actinic Keratosis	Immunotherapy: Doub	le-Blind, Randomized Clinical Trial
6. Manuscript Identifying Number (if you kr 89820-JCI-CMED	now it)		
Section 2. The Work Under Co	onsideration for Public	cation	
Did you or your institution at any time rece any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not limited to grants, da		
Are there any relevant commets of interes			
Section 3. Relevant financial	activities outside the s	submitted work.	
Place a check in the appropriate boxes i of compensation) with entities as descri clicking the "Add +" box. You should rep Are there any relevant conflicts of interes	bed in the instructions. Us port relationships that wer	se one line for each enti	ity; add as many lines as you need by
Section 4. Intellectual Proper	ty Patents & Copyric	ghts	
Do you have any patents, whether plan	ned, pending or issued, br	oadly relevant to the w	rork? Yes V No

Schaffer 2



Section 5.	Relationships not covered above
	relationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
=	owing relationships/conditions/circumstances are present (explain below): ationships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. Irnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abbelow.	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Dr. Schaffer has	nothing to disclose.

Evaluation and Feedback



Section 1. Identifying Inform	ation			
Given Name (First Name) Arturo	2. Surname (Last Name) Saavedra		3. Date 29-August-2016	
4. Are you the corresponding author?	Yes No	Corresponding Author' Shadmehr Demehri	s Name	
5. Manuscript Title Calcipotriol and 5-Fluorouracil Combina	ition for Actinic Keratosis I	mmunotherapy: Doub	le-Blind, Randomized Clir	nical Trial
6. Manuscript Identifying Number (if you kn 89820-JCI-CMED	ow it)			
Section 2. The Work Under Co	onsideration for Public	ation		
Did you or your institution at any time receinany aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not limited to grants, da			
Section 3. Relevant financial a	activities outside the s	ubmitted work.		
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication . Are there any relevant conflicts of interest? Yes Vo				
NO. WILLY LANGER				Art V
Section 4. Intellectual Proper	ty Patents & Copyrig	hts		
Do you have any patents, whether plann	ned, pending or issued, bro	oadly relevant to the w	ork? Yes No	



Section 5.			Total Control of the	
	Relationships not covered above			
	relationships or activities that readers could encing, what you wrote in the submitted w		ienced, or that give the	appearance of
	wing relationships/conditions/circumstance			
No other rela	tionships/conditions/circumstances that p	resent a potential conf	flict of interest	
	anuscript acceptance, journals will ask auth rnals may ask authors to disclose further in			disclosure statements.
Section 6.	Disclosure Statement			
Based on the abo	ove disclosures, this form will automatically	generate a disclosure	statement, which will a	appear in the box
10 to				
Dr. Saavedra has	s nothing to disclose.			edica i apportan

Evaluation and Feedback



Section 1. Identifying Inform	mation	
Given Name (First Name) Michael	2. Surname (Last Name) 3. Date Wallendorf 29-Augu	ist-2016
4. Are you the corresponding author?	Yes No Corresponding Author's Name Shadmehr Demehri	garana darenta Mandona eta bak
5. Manuscript Title Calcipotriol and 5-Fluorouracil Combin	nation for Actinic Keratosis Immunotherapy: Double-Blind, Rand	omized Clinical Trial
6. Manuscript Identifying Number (if you k 89820-JCI-CMED	know it)	
ingestern to the factor		
Section 2. The Work Under C	Consideration for Publication	
Did you or your institution at any time recany aspect of the submitted work (includin statistical analysis, etc.)? Are there any relevant conflicts of interesting the state of the state	reive payment or services from a third party (government, commercial, page but not limited to grants, data monitoring board, study design, manurest?	private foundation, etc.) for uscript preparation,
Section 3. Relevant financia	l activities outside the submitted work.	
of compensation) with entities as desc	s in the table to indicate whether you have financial relationships cribed in the instructions. Use one line for each entity; add as ma eport relationships that were present during the 36 months pr rest? Yes No	ny lines as you need by
Section 4. Intellectual Prope	erty Patents & Copyrights	
Do you have any patents, whether plan	nned, pending or issued, broadly relevant to the work?	✓ No



Section 5.	Relationships not covered above	
	relationships or activities that readers could perceive to have influenced, or that give the uencing, what you wrote in the submitted work?	appearance of
_	owing relationships/conditions/circumstances are present (explain below): lationships/conditions/circumstances that present a potential conflict of interest	ji na a
	nanuscript acceptance, journals will ask authors to confirm and, if necessary, update their urnals may ask authors to disclose further information about reported relationships.	disclosure statements.
Section 6.	Disclosure Statement	No true A ex
below.	pove disclosures, this form will automatically generate a disclosure statement, which will a	
Dr. Wallendorf h	has nothing to disclose.	E 8 200 3 =

Evaluation and Feedback



Section 1.	Identifying Inforn	nation			
1. Given Name (Fi	rst Name)	2. Surname (Last Name) Cornelius	ing sequences	3. Date 29-August-2016	fines in the
÷	responding author?	Yes No	Corresponding Aut Shadmehr Demeh		es e e e e e e e e e e e e e e e e e e
Manuscript Title Calcipotriol and		ation for Actinic Keratosi	s Immunotherapy: Do	ouble-Blind, Randomized C	linical Trial
6. Manuscript Ider 89820-JCI-CMED	ntifying Number (if you k	now it)			
11 4 0					
Section 2.	The Work Under C	onsideration for Pub	lication		
statistical analysis,			aata monitoring board, s	study design, manuscript pre	paration,
Section 3.	Relevant financial	activities outside the	submitted work.		
of compensation clicking the "Add) with entities as descr	ibed in the instructions. I port relationships that w	Jse one line for each	ncial relationships (regardl entity; add as many lines a he 36 months prior to pu	s you need by
Section 4.	Intellectual Proper	rty Patents & Copyr	ights		
If yes, please fill o	1077 (2)			e work?	
Paten	t ? Pendi	ng? Issued? Licensed	Royalties Licens	see? Comments	
PCT/US2015/049434					

Cornelius 2



Section 5.	Relationships not covered above	
	relationships or activities that readers could perceive to have influencing, what you wrote in the submitted work?	uenced, or that give the appearance of
_	wing relationships/conditions/circumstances are present (explaintionships/conditions/circumstances that present a potential con	
	anuscript acceptance, journals will ask authors to confirm and, if rnals may ask authors to disclose further information about repo	
Section 6.	Disclosure Statement	
Based on the abo below.	ove disclosures, this form will automatically generate a disclosure	No. 18 to the second second
Dr. Cornelius rep	oorts In addition, Dr. Cornelius has a patent PCT/US2015/049434	issued.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Cornelius 3



Section 1.	Identifying Inforn	nation			131615		
Given Name (First Name) Shadmehr		2. Surname (Last Name) Demehri	1 1	3. Date 29-August-2016			
4. Are you the corresponding author?		Yes No					
5. Manuscript Title Calcipotriol and 5-Fluorouracil Combination for Actinic Keratosis Immunotherapy: Double-Blind, Randomized Clinical Trial							
6. Manuscript Idea 89820-JCI-CMED	ntifying Number (if you kr)	now it)					
Section 2.	The Work Under C	onsideration for Publ	ication				
statistical analysis, Are there any rela	evant conflicts of intere		submitted work		- to t		
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication . Are there any relevant conflicts of interest? Yes No							
Section 4.	Intellectual Proper	ty Patents & Copyr	ghts				
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No If yes, please fill out the appropriate information below. If you have more than one entity press the "ADD" button to add a row. Excess rows can be removed by pressing the "X" button.							
Paten	t ? Pendii	ng? Issued? Licensed?	Royalties Licer	comments			
CT/US2015/049434							



Section 5.	Relationships not covered above	
	elationships or activities that readers could perceive to have influenced, or that give the a encing, what you wrote in the submitted work?	appearance of
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):	
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest	
At the time of me	anuserint accontance journals will ask authors to confirm and if necessary undate their s	licelocure statements
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their c rnals may ask authors to disclose further information about reported relationships.	iisclosure statements.
Section 6.	Disclosure Statement	
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will a	opear in the box
below.		
A L X	of the state of th	TAMES WENT
Dr. Demehri repo	orts In addition, Dr. Demehri has a patent PCT/US2015/049434 issued.	ade star a a
		Verse

Evaluation and Feedback